Behind the Science magazine

Antibody-drug conjugates: Advancing the search for more targeted cancer treatment

Who we are

As a focused biopharma company, we discover, develop and deliver medicines and vaccines to create value for patients and shareholders. We aim to positively impact the health of 2.5 billion people by the end of the decade.

Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.

Purpose, strategy and culture

Why invest in GSK?

Respiratory, immunology and inflammation

deaths each year due to lung diseases

Go to respiratory, immunology and inflammation

Oncology

~10m

people die from cancer each year

Go to oncology

HIV

40m

people living with HIV globally

Go to HIV

Infectious diseases

1 in 7

deaths globally caused by infectious disease

Go to infectious diseases

Behind the Science

Discover how we're getting ahead

‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’

‘Finding the right treatment for my asthma and nasal polyps has transformed my life. I hope my experience can help others achieve the same’

‘Long-acting therapies are no longer the future of HIV treatment – they are the now’

‘Cancer doesn’t have to be a deadly disease – it’s our goal to make it curable’

‘This could be a golden moment’: Is prevention the ‘medicine’ we need to end the HIV epidemic?

‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options

Read our magazine

Life at GSK

Find out what it's like to work with us

Make a difference with us

Do your best work with us

Be yourself with us

Careers at GSK

Positively impacting society and the planet

Access

We aim to make our products available as widely as possible through responsible pricing, strategic access programmes and partnerships

Access

Twin sisters from Zanzibar looking at camera

Global health and health security

Our innovation and partnerships help protect people around the world by tackling global health threats.

Global health and health security

Environment

We're committed to work towards a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.

Environment

Inclusion

To be a successful business and deliver positive health impact at scale, we must meet patients’ needs with research that includes those impacted by the disease under study, attract and retain the best talent regardless of background, and support all GSK people to thrive.

Inclusion

Ethical standards

Conducting ourselves in the right way, and making sure those we work with do likewise, sustains trust in our work and strengthens our business.

Ethical standards

Product governance

Ensuring the quality, safety and reliable supply of our products protects our patients and enables our continued success.

Product governance

INVESTORS

We announced our full year and fourth quarter 2025 results on Wednesday 4 February

View latest results